Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database

Abstract

Simple Summary Breast cancer is the most common cancer among women, and those carrying inherited mutations in their BRCA1 or BRCA2 genes face a significantly higher lifetime risk of developing the disease. Olaparib, a targeted therapy that blocks proteins that cancer cells rely on for DNA repair, was approved in 2022 for use after surgery in high-risk, HER2-negative early-stage breast cancer patients with these inherited mutations. While clinical trials have demonstrated substantial survival benefits, limited real-world data exist on how olaparib is used in routine clinical practice. This study analyzed US insurance claims data and found that, among 176 olaparib-treated patients, most remained on treatment for the recommended 12-month course, while few required dose reductions or permanently discontinued therapy. Nearly half of these patients received olaparib alongside other therapies. These findings can help guide clinical decision-making, highlight opportunities to improve patient support, and inform future studies evaluating the safety and effectiveness of olaparib combination regimens.